Photobiomodulation to prevent oral mucositis during head-and-neck radiotherapy

Evidence label: Positive randomized signal, protocol-specific · Clinical goal: prevent severe oral mucositis during high-dose radiotherapy

Evidence at a glance

Population: 85 people receiving high-dose intensity-modulated radiotherapy for head-and-neck cancer, with or without chemotherapy, at 12 US sites.
Intervention: a defined intraoral light-emitting-diode photobiomodulation protocol before each radiation treatment versus sham.
Result: severe oral mucositis occurred less often with active treatment; no device-related adverse events were reported.

What was studied

The multicenter double-blind randomized trial assigned 42 participants to photobiomodulation and 43 to sham. Treatment was delivered for 10 minutes before each radiotherapy session.

The device, wavelength, power, dose, anatomic field and timing are part of the intervention. Results from one protocol should not be assumed for untested home devices or settings.

What the evidence shows

Across six weeks of radiotherapy, severe oral mucositis occurred in 36.8% of the active group and 57.1% of the sham group (P=.046). Two weeks after radiotherapy, the corresponding proportions were 10.8% and 36.4% (P=.042).

No device-related adverse events were reported. This is supportive-care evidence; it says nothing about tumor response, recurrence or survival.

Limits and uncertainty

The study was modest in size, and its benefit estimate is close to the conventional threshold for statistical significance. Replication and implementation under validated protocols matter.

Professional guidance is protocol-specific. A clinic should match the relevant wavelength, dose and treatment field rather than treating “red light” as one uniform intervention.

Safety and practical context

Photobiomodulation should be delivered under an oncology-supportive-care protocol. Eye protection, device hygiene, treated anatomy and dose all matter.

Do not direct light over an unassessed lesion or substitute a consumer device for dental and oncology care. Pain, dehydration, infection and inability to swallow require prompt clinical assessment.

Questions for the care team

Does the clinic use a protocol supported for my radiation setting?
Who will document wavelength, dose, treatment field and quality control?
How will oral care, pain control, nutrition and infection monitoring continue alongside it?

Sources

Literature searched: October 14, 2026 · Record appraised: October 14, 2026

Educational evidence summary, not personal medical advice. Supportive approaches should complement—not replace—appropriate cancer treatment and symptom management.